23/11/2022	
Name: Mariano Provencio	
script Title: Real-world treatment patterns and survival outcomes for patients with stage III non-small cell lung r in Spain: a nationwide cohort study	
in Spain. a nationwide conditistudy	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

Manuscript number (if known): TLCR-23-176-R1

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	by Bristol Myers Squibb n of study materials, writing, article ng charges, etc.) by Bristol Myers Squibb BMS BMS	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	

4	Consulting fees	None	
5	Payment or honoraria for	None	
	lectures, presentations,	BMS, Astra Zeneca, Pfizer,	
	speakers bureaus,	Takeda, Roche, MSD,	
	manuscript writing or educational events	Janssen	
c	Payment for expert	x None	
6	testimony	x_None	
	testimony		
7	Support for attending	None	
,	meetings and/or travel		
		BMS, Astra Zeneca, Pfizer,	
		Takeda, Roche, MSD,	
		Janssen	
8	Patents planned, issued or	xNone	
	pending		
9	Participation on a Data	x_None	
	Safety Monitoring Board or		
10	Advisory Board	N.	
10	Leadership or fiduciary role	xNone	
	in other board, society, committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	x None	
12	Receipt of equipment,	_xNone	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	xNone	
	financial interests		

MP reports payment or honoraria for lectures, presentations, speakers' bureaus, manuscript writing or educational events and support for attending meetings and/or travel from AstraZeneca, Bristol Myers Squibb, Janssen, MSD, Pfizer, Roche and Takeda.

Please place an "X" next to the following statement to indicate your agreement:

Date	22 Nov 2022
Youi	Name: Enric Carcereny
	script Title: Real-world treatment patterns and survival outcomes for patients with stage III non-small cell lung r in Spain: a nationwide cohort study
Man	script number (if known): TLCR-23-176-R1
relat part to tr relat	interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are d to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third is whose interests may be affected by the content of the manuscript. Disclosure represents a commitment insparency and does not necessarily indicate a bias. If you are in doubt about whether to list a posship/activity/interest, it is preferable that you do so.
	ollowing questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> script only.
to th	uthor's relationships/activities/interests should be <u>defined broadly</u> . For example, if your manuscript pertains epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive ration, even if that medication is not mentioned in the manuscript.
	n #1 below, report all support for the work reported in this manuscript without time limit. For all other items, me frame for disclosure is the past 36 months.
	Name all entities with whom you have this (e.g., if payments were made to you or to your institution)

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	This work was supported by Bristol Myers Squibb	
2	Grants or contracts from any entity (if not indicated in item #1 above).	Time frame: pastNone	36 months
3	Royalties or licenses	None	

4	Consulting fees	None	
5	Payment or honoraria for	None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or educational events		
6	Payment for expert	None	
O	testimony		
	testimon,		
7	Support for attending	None	
	meetings and/or travel		
	ζ ,		
8	Patents planned, issued or	None	
	pending		
	. 0		
9	Participation on a Data	None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy		
11	group, paid or unpaid	A.	
11	Stock or stock options	None	
12	Receipt of equipment,	None	
12	materials, drugs, medical	None	
	writing, gifts or other		
	services		
13	Other financial or non-	None	
	financial interests		
Plea	ise summarize the above co	nflict of interest in the fol	owing box:

Please place an "X" next to the following statement to indicate your agreement:

Date: December 15th, 2022

Your Name: Rafael López Castro

Manuscript Title: Real-world treatment patterns and survival outcomes for patients with stage III non-small cell lung

cancer in Spain: a nationwide cohort study

Manuscript number (if known): TLCR-23-176-R1

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	This work was supported by Bristol Myers Squibb	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	

			1
4	Consulting fees	None	-
	3 11 1 3 11 1		1
			1
5	Payment or honoraria for	Takeda	
	lectures, presentations,	Pierre-Fabre	
	speakers bureaus,	AstraZeneca	
	manuscript writing or	MSD	
	educational events		
		Roche	-
		BMS	
		Novartis	
		Aristo	
6	Payment for expert	None	
	testimony		
7	Support for attending	Takeda; Novartis; Roche	
	meetings and/or travel		4
			-
8	Patents planned, issued or	None	
	pending		
			_
9	Participation on a Data	None	_
	Safety Monitoring Board or		4
	Advisory Board		4
10	Leadership or fiduciary role	None	-
	in other board, society,		-
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	None	i
11	Stock of Stock Options	Holic	i
12	Receipt of equipment,	None	1
	materials, drugs, medical		1
	writing, gifts or other		1
	services		
13	Other financial or non-	None	1
	financial interests		1
		-	

RLC reports payment or honoraria for lectures, presentations, speakers' bureaus, manuscript writing or educational events from Aristo, AstraZeneca, Bristol Myers Squibb, MSD, Novartis, Pierre-Fabre, Roche and Takeda; and support for attending meetings and/or travel from Novartis, Roche and Takeda.

Please place an "X" next to the following statement to indicate your agreement:				
☑ I certify that I have answered every question and have not altered the wording of any of the questions on this form				

Date: 11/3/2022	
Your Name: Virginia Calvo de Juan	
Manuscript Title: Real-world treatment patterns	and survival outcomes for patients with stage III non-small cell lung

cancer in Spain: a nationwide cohort study

Manuscript number (if known): TLCR-23-176-R1

Date: 11/9/2022

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning of the work	
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	This work was supported by Bristol Myers Squibb	
		Time frame: past 36 months	
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

5	Payment or honoraria for lectures, presentations,		
	speakers bureaus,	ROCHE, BMS, MSD, ASTRAZENECA, TAKEDA,	
	manuscript writing or educational events	PFIZER, LILLY, BOEHRINGER INGELHEIM	
6	Payment for expert testimony	XNone	
	testimony		
7	Support for attending meetings and/or travel	XNone	
	,		
8	Patents planned, issued or	X_None	
	pending		
0	Dauticipation on a Data	V Nana	
9	Participation on a Data Safety Monitoring Board or	XNone	
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	_XNone	
12	Receipt of equipment,	_X_None	
	materials, drugs, medical writing, gifts or other		
	services		
13	Other financial or non-	_XNone	
	financial interests		

VC reports payment or honoraria for lectures, presentations, speakers' bureaus, manuscript writing or educational events from AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Lilly, MSD, Pfizer, Roche and Takeda.

Please place an "X" next to the following statement to indicate your agreement:

Date:1/23/2023			
Your Name:Delvys Rodriguez-Abreu			
Manuscript Title: Real-world treatment patterns and survival outcomes for patients with stage III non-small cell lung cancer in Spain: a nationwide cohort study			
Manuscript number (if known): TLCR-23-176-R1			
In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment			

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> manuscript only.

to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a

relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	This work was supported by Bristol Myers Squibb	
2	Grants or contracts from	Time frame: past None	36 months
	any entity (if not indicated in item #1 above).	NOTIC	
3	Royalties or licenses	None	

4	Consulting fees	BMS, MSD, ROCHE, ASTRA ZENECA, BOEHRINGER INGELHEIM, NOVARTIS, Lilly	Consultant or Advisory Board
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	BMS, MSD, ROCHE, ASTRA ZENECA, BOEHRINGER INGELHEIM, NOVARTIS, Lilly	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	MSD, Roche, Novartis	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non- financial interests	None	

DRA reports consulting fees and payment or honoraria for lectures, presentations, speakers' bureaus, manuscript writing or educational events from AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Lilly, MSD, Novartis and Roche. DRA also reports support for attending meetings and/or travel from MSD, Novartis and Roche.

Please place an "X" next to the following statement to indicate your agreement:

Date:_____9-11-2022____

Grants or contracts from

item #1 above).

Royalties or licenses

3

any entity(if not indicated in

You	Your Name:Manuel Cobo				
	Manuscript Title: Real-world treatment patterns and survival outcomes for patients with stage III non-small cell lung cancer in Spain: a nationwide cohort study				
Mar	uscript number (if known):	TLCR-23-176-R1			
relate part	ted to the content of your miles whose interests may be	nanuscript. "Related" mear affected by the content of ecessarily indicate a bias. I	relationships/activities/interests listed below that are any relation with for-profit or not-for-profit third the manuscript. Disclosure represents a commitment of you are in doubt about whether to list a so.		
	following questions apply to uscript only.	o the author's relationship	s/activities/interestsas they relate to the <u>current</u>		
to th	The author's relationships/activities/interests should be <u>defined broadly</u> . For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.				
	em #1 below, report all sup time frame for disclosure is	•	in this manuscript without time limit. For all other items,		
	Name all entities with whom you have this relationship or indicate none (add rows as needed) Specifications/Comments (e.g., if payments were made to you or to your institution)				
	Time frame: Since the initial planning of the work				
1					

Time frame: past 36 months

none

none

None

None

4	Consulting fees	None	none
5	Payment or honoraria for	None	none
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or educational events		
6	Payment for expert	None	none
U	testimony	None	none
	testimony		
7	Support for attending	None	none
,	meetings and/or travel		none -
	3 ,		
8	Patents planned, issued or	None	none
	pending		
9	Participation on a Data	None	none
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	None	none
	in other board, society, committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	none
12	Receipt of equipment,	None	none
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	None	none
13	financial interests	10110	none
	a. interests		

none

Please place an "X" next to the following statement to indicate your agreement:

Date: 12/19/2022

Your Name: Ana Laura Ortega Granados

Manuscript Title: Real-world treatment patterns and survival outcomes for patients with stage III non-small cell lung

cancer in Spain: a nationwide cohort study

Manuscript number (if known): TLCR-23-176-R1

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	This work was supported by Bristol Myers Squibb	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	

4	Consulting fees	None	
5	Payment or honoraria for	None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or educational events		
6	Payment for expert	None	
O	testimony		
	testimon,		
7	Support for attending	None	
	meetings and/or travel		
	ζ ,		
8	Patents planned, issued or	None	
	pending		
	. 0		
9	Participation on a Data	None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy		
11	group, paid or unpaid	A.	
11	Stock or stock options	None	
12	Receipt of equipment,	None	
12	materials, drugs, medical	None	
	writing, gifts or other		
	services		
13	Other financial or non-	None	
	financial interests		
Plea	ise summarize the above co	nflict of interest in the fol	owing box:

Please place an "X" next to the following statement to indicate your agreement:

Date:	20 DEC 2022	
Your Name:	_REYES BERNABE CARO	

Manuscript Title: Real-world treatment patterns and survival outcomes for patients with stage III non-small cell lung cancer in Spain: a nationwide cohort study

Manuscript number (if known): TLCR-23-176-R1

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	This work was supported by Bristol Myers Squibb	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	

4	Consulting fees	None	
5	Payment or honoraria for	None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or educational events		
6	Payment for expert	None	
O	testimony		
	testimon,		
7	Support for attending	None	
	meetings and/or travel		
	<i>,</i>		
8	Patents planned, issued or	None	
	pending		
	. 0		
9	Participation on a Data	None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy		
11	group, paid or unpaid	A.	
11	Stock or stock options	None	
12	Receipt of equipment,	None	
12	materials, drugs, medical	None	
	writing, gifts or other		
	services		
13	Other financial or non-	None	
	financial interests		
Plea	ise summarize the above co	nflict of interest in the fol	owing box:

Please place an "X" next to the following statement to indicate your agreement:

Date:_9/NOV/2022

Your Name: MARÍA GUIRADO RISUEÑO

Manuscript Title: Real-world treatment patterns and survival outcomes for patients with stage III non-small cell lung cancer in Spain: a nationwide cohort study

Manuscript number (if known): TLCR-23-176-R1

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	This work was supported by Bristol Myers Squibb	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	X None	
3	Royalties or licenses	X None	

4	Consulting fees	X None		
-				
5	Payment or honoraria for lectures, presentations,	X None		
	speakers bureaus,			
	manuscript writing or			
	educational events			
6	Payment for expert	X None		
	testimony			
_				
7	Support for attending meetings and/or travel	X None		
	G ,			
8	Patents planned, issued or	X None		
	pending			
9	Participation on a Data	X None		
	Safety Monitoring Board or Advisory Board			
10	Leadership or fiduciary role	X None		
	in other board, society,			
	committee or advocacy			
	group, paid or unpaid			
11	Stock or stock options	X None		
12	Receipt of equipment,	X None		
	materials, drugs, medical	55		
	writing, gifts or other services			
13	Other financial or non-	X None		
	financial interests			

None.			

Please place an "X" next to the following statement to indicate your agreement:

Date	e:December 14 th 202	2			
You	Your Name:Bartomeu Massutí MD				
	nuscript Title: Real-world tre er in Spain: a nationwide co		val outcomes for patients with stage III non-small cell lung		
Mar	nuscript number (if known):	TLCR-23-176-R1			
relate part	ted to the content of your n ies whose interests may be	nanuscript. "Related" mean affected by the content of ecessarily indicate a bias.	relationships/activities/interests listed below that are ns any relation with for-profit or not-for-profit third the manuscript. Disclosure represents a commitment If you are in doubt about whether to list a so.		
	following questions apply touscript only.	o the author's relationship	s/activities/interests as they relate to the <u>current</u>		
to the med	The author's relationships/activities/interests should be <u>defined broadly</u> . For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript. In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.				
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)		
		Time frame: Since the initia	l planning of the work		
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	This work was supported by Bristol Myers Squibb			
		Time frame: past	36 months		

Grants or contracts from

in item #1 above).

Royalties or licenses

3

any entity (if not indicated

None

None

4	Consulting fees	Astra Zeneca Roche, Sanofi,	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	Roche, Astra-Zeneca, Boehringer, Takeda, MSD	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	MSD, Astra Zeneca,	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non- financial interests	None	

BM reports consulting fees from AstraZeneca, Roche and Sanofi. BM also reports payment or honoraria for lectures, presentations, speakers' bureaus, manuscript writing or educational events from AstraZeneca, Boehringer Ingelheim, MSD, Roche and Takeda; and support for attending meetings and/or travel from AstraZeneca and MSD.

Please place an "X" next to the following statement to indicate your agreement: X

Date:	_22/11/2022
Your Name:ED	EL DEL BARCO MORILLO
•	Real-world treatment patterns and survival outcomes for patients with stage III non-small cell lung nationwide cohort study

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

Manuscript number (if known): TLCR-23-176-R1

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	This work was supported by Bristol Myers Squibb	
2	Grants or contracts from	Time frame: past None	36 months
	any entity (if not indicated in item #1 above).	NOTIC	
3	Royalties or licenses	None	

4	Consulting fees	None	
4	Consulting rees	None	
_			
5	Payment or honoraria for	None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	None	
	testimony		
7	Support for attending meetings and/or travel	None	
	,		
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment,	None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	None	
	financial interests	_	
Plea	ise summarize the above co	nflict of interest in the foll	owing hox:

N	ne	

Please place an "X" next to the following statement to indicate your agreement:

Date:	11/Nov/2022
Your Name:	Joaquim Bosch-Barrera
•	Real-world treatment patterns and survival outcomes for patients with stage III non-small cell lung a nationwide cohort study
Manuscript num	ber (if known): TLCR-23-176-R1
related to the co parties whose in to transparency	f transparency, we ask you to disclose all relationships/activities/interests listed below that are ontent of your manuscript. "Related" means any relation with for-profit or not-for-profit third sterests may be affected by the content of the manuscript. Disclosure represents a commitment and does not necessarily indicate a bias. If you are in doubt about whether to list a ivity/interest, it is preferable that you do so.
The following qu	uestions apply to the author's relationships/activities/interests as they relate to the current

manuscript only.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	This work was supported by Bristol Myers Squibb	BMS
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	Pfizer (Institution) Roche (Institution)
3	Royalties or licenses	XNone	

4	Consulting fees	None	
5	Payment or honoraria for	x_None	Astrazeneca
	lectures, presentations,		Sanofi
	speakers bureaus, manuscript writing or		BMS, MSD, Roche, Boehringer-Ingelheim
	educational events		
6	Payment for expert	X None	
	testimony		
	,		
7	Support for attending	None	Takeda, MSD, Roche
	meetings and/or travel		
8	Patents planned, issued or	X_None	
	pending		
	5	V N	
9	Participation on a Data Safety Monitoring Board or	_XNone	
	Advisory Board		
10	Leadership or fiduciary role	X None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	_XNone	
12	Descint of agricument	V None	
12	Receipt of equipment, materials, drugs, medical	XNone	
	writing, gifts or other		
	services		
13	Other financial or non-	XNone	
	financial interests	_	

JB-B reports institutionally awarded grants and personal fees from Pfizer and Roche. JB-B also reports payment or honoraria for lectures, presentations, speakers' bureaus, manuscript writing or educational events from AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, MSD, Roche and Sanofi; and support for attending meetings and/or travel from MSD, Roche and Takeda.

Please place an "X" next to the following statement to indicate your agreement:

Date:	10/11/2022
Your Name	CARLOS CAMPS HERRERO
•	Title: Real-world treatment patterns and survival outcomes for patients with stage III non-small cell lung ain: a nationwide cohort study

Manuscript number (if known): TLCR-23-176-R1

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	This work was supported by Bristol Myers Squibb	
2	Grants or contracts from any entity (if not indicated in item #1 above).	Time frame: pastNone	36 months
3	Royalties or licenses	None	

4	Consulting fees	None	
4	Consulting rees	None	
_			
5	Payment or honoraria for	None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	None	
	testimony		
7	Support for attending meetings and/or travel	None	
	,		
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment,	None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	None	
	financial interests	_	
Plea	ise summarize the above co	nflict of interest in the foll	owing hox:

N	ne	

Please place an "X" next to the following statement to indicate your agreement:

Date:9/11/2022	
Your Name: Robert Carroll_	
Manuscript Title: Real-world treatment patterns and survival outcomes for patients with stage III non-small cell lung cancer in Spain: a nationwide cohort study	
Manuscript number (if known): TLCR-23-176-R1	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	This work was supported by Bristol Myers Squibb	I am a full-time employee of Bristol Myers Squibb, the study sponsor
2	Grants or contracts from	Time frame: past None	36 months
	any entity (if not indicated in item #1 above).		
3	Royalties or licenses	None	

4	Consulting fees	None	
4	consulting lees	None	
_			
5	Payment or honoraria for	None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
_	educational events		
6	Payment for expert	None	
	testimony		
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment,	None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	None	
	financial interests		

I am a full-time employee of Bristol Myers Squibb, the study sponsor

Please place an "X" next to the following statement to indicate your agreement:

Date:	_28/11/2022_	

Your Name: Caroline Rault

Manuscript Title: Real-world treatment patterns and survival outcomes for patients with stage III non-small cell lung cancer in Spain: a nationwide cohort study

Manuscript number (if known): TLCR-23-176-R1

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	This work was supported by Bristol Myers Squibb	pranning of the work
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	

4	Consulting fees	None	
5	Payment or honoraria for	None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
_	educational events		
6	Payment for expert	None	
	testimony		
_			
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	None	
11	Stock of Stock options	None	
12	Receipt of equipment,	None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	None	
	financial interests		
Plea	ase summarize the above co	nflict of interest in the follo	owing hox.

None			

Please place an "X" next to the following statement to indicate your agreement:

Date:Nov 11, 2022	-
Your Name:CARLOS CHAIB TORRALBA	_
Manuscript Title: Real-world treatment patterns and survival outcomes for patients with stage III non-small cell lung	

Manuscript number (if known): TLCR-23-176-R1

cancer in Spain: a nationwide cohort study

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	This work was supported by Bristol Myers Squibb	BMS - Employee
2		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	

4	Consulting fees	None	
5	Payment or honoraria for	None	
	lectures, presentations, speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	None	
	testimony		
	·		
7	Support for attending	None	
	meetings and/or travel		
	g ,		
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	Yes	
12	Receipt of equipment,	None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	None	
	financial interests		

I am BMS employee, also I receive company stocks as part of my annual compensation

Please place an "X" next to the following statement to indicate your agreement:

Date:_January 24, 2023	
Your Name: John R. Penrod	
Tour NameJohn K. Femou	

Manuscript Title: Real-world treatment patterns and survival outcomes for patients with stage III non-small cell lung cancer in Spain: a nationwide cohort study

Manuscript number (if known): TLCR-23-176-R1

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	This work was supported by Bristol Myers Squibb	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	

4	Consulting fees	None		
5	Payment or honoraria for	None		
	lectures, presentations,			
	speakers bureaus,			
	manuscript writing or			
	educational events			
6	Payment for expert	None		
	testimony			
	testimony			
7	Support for attending	None		
,	meetings and/or travel	None		
	meetings and/or travel			
8	Patents planned, issued or	None		
	pending			
9	Participation on a Data	None		
	Safety Monitoring Board or			
	Advisory Board			
10	Leadership or fiduciary role	None		
10	in other board, society,			
	committee or advocacy			
	group, paid or unpaid			
11	Stock or stock options	Stock ownership in Bristol		
11	Stock of Stock options	Myers Squibb		
		iviyets squibb		
12	Descint of anylows art	Nege		
12	Receipt of equipment,	None		
	materials, drugs, medical			
	writing, gifts or other			
4.5	services			
13	Other financial or non-	Employment at Bristol		
	financial interests	Myers Squibb		
Plea	Please summarize the above conflict of interest in the following box:			

I disclose employment with and stock ownership in Brisol Myers Squibb		

Please place an "X" next to the following statement to indicate your agreement:

I certify that I have answered every question and have not altered the wording of any of the questions on this form X

Date:	1/3/2023		
Your Name:	Lien Vo		
•	e: Real-world treatment patterns and survival outcomes for patients with stage III non-small cell lung a nationwide cohort study		
Manuscript number (if known): TLCR-23-176-R1			
In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are			

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	This work was supported by Bristol Myers Squibb	
2	Grants or contracts from any entity (if not indicated in item #1 above).	Time frame: pastNone	36 months
3	Royalties or licenses	None	

4	Consulting fees	None	
	S		
5	Payment or honoraria for	None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	None	
	testimony		
7	Support for attending	None	
	meetings and/or travel		
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	BMS	
12	Receipt of equipment,	None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	BMS	Employee of BMS
	financial interests		

Restricted stock options from BMS; BMS employee	

Please place an "X" next to the following statement to indicate your agreement:

Date:_15/11/2022		
Your Name:Eleanor Ralphs		

Manuscript Title: Real-world treatment patterns and survival outcomes for patients with stage III non-small cell lung cancer in Spain: a nationwide cohort study

Manuscript number (if known): TLCR-23-176-R1

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	This work was supported by Bristol Myers Squibb	IQVIA
2		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	

4	Consulting fees	None	
5	Payment or honoraria for	None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or educational events		
6	Payment for expert	None	
U	testimony	None	
	testimony		
7	Support for attending	None	
,	meetings and/or travel		
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy		
11	group, paid or unpaid	None	
11	Stock or stock options	None	
12	Receipt of equipment,	None	
14	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	None	
	financial interests		

En	ployee of IQVIA

Please place an "X" next to the following statement to indicate your agreement:

Date:	November 30, 2022	
Your Name: Melinda J D	aumont	
Manuscript Title: Real-w cancer in Spain: a nation	orld treatment patterns and survival outcomes for patients with swide cohort study	tage III non-small cell lung
Manuscript number (if k	(nown): TLCR-23-176-R1	
related to the content o parties whose interests	arency, we ask you to disclose all relationships/activities/interes f your manuscript. "Related" means any relation with for-profit omay be affected by the content of the manuscript. Disclosure repes not necessarily indicate a bias. If you are in doubt about whet	or not-for-profit third presents a commitment

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	This work was supported by Bristol Myers Squibb	BMS
2	Grants or contracts from any entity (if not indicated in item #1 above).	Time frame: pastNone	36 months
3	Royalties or licenses	None	

4	Consulting food	None	
4	Consulting fees	None	
5	Payment or honoraria for	None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	None	
	testimony		
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society, committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical	None	
	writing, gifts or other		
	services		
13	Other financial or non-	None	
	financial interests		

I am an employee of Bristol-Myers Squibb, the sponsor of the research reported in this manuscript.		

Please place an "X" next to the following statement to indicate your agreement: X